https://sfsep.org/ressource/ 2026-04-14T09:39:58+00:00 https://sfsep.org/ressource/recommandations-vaccinales-dans-la-sep/ 2026-04-14T09:39:58+00:00 https://sfsep.org/ressource/controverse-est-il-possible-darreter-un-traitement-de-fond/ 2026-04-14T09:34:27+00:00 https://sfsep.org/ressource/nouveau-traitement-apres-cladribine/ 2026-04-13T13:17:51+00:00 https://sfsep.org/ressource/validation-en-rcp-dun-traitement-de-2e-ligne/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-1ere-ligne-apres-fingolimod/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-natalizumab-ou-ocrelizumab-apres-fingolimod/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-1ere-ligne-apres-natalizumab/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-fingolimod-ou-ocrelizumab-apres-natalizumab/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/irm-trimestrielle-apres-natalizumab-et-jcv-positif/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-1ere-ligne-apres-ocrelizumab/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/nfs-trimestrielle-apres-mitoxantrone/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-2e-ligne-apres-ocrelizumab/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/surveillance-dermatologique-et-gynecologique-sous-azathioprine/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-1ere-ligne-apres-mitoxantrone/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/surveillance-dermatologique-sous-mycophenolate-mofetil/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/relais-2e-ligne-apres-mitoxantrone/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/antecedents-familiaux-de-cancer-et-oncogenetique/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/nouveau-traitement-apres-alemtuzumab/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/syndrome-de-susceptibilite-genetique-et-risque-cancereux/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/discussion-pluridisciplinaire-en-cas-de-susceptibilite-genetique/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/nouveau-traitement-de-1ere-ligne-sans-delai/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/attendre-800-mm3-apres-dimethyl-fumarate/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/elimination-du-teriflunomide-et-grossesse/ 2026-04-13T13:17:48+00:00 https://sfsep.org/ressource/traitements-oncologiques-non-contre-indiques/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/arret-du-traitement-de-fond-si-chimiotherapie-efficace-sur-la-sep/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/arret-du-traitement-de-fond-avant-greffe-de-cellules-souches/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/reprise-du-traitement-de-fond-apres-cancer/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/surveillance-neurologique-sous-inhibiteur-de-checkpoint/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/reintroduction-du-traitement-de-fond/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/traitement-de-fond-en-rct-sous-inhibiteur-de-checkpoint/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/strategie-sep-collegiale-apres-cancer/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/pas-de-bilan-specifique-cancer-au-suivi/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/depistage-du-cancer-en-population-generale/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/surveillance-dermatologique-et-gynecologique-sous-s1p/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/recherche-des-antecedents-et-facteurs-de-risque-de-cancer/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/pas-de-bilan-specifique-cancer-avant-ces-traitements/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/depistage-hpv-et-examen-dermatologique-avant-s1p/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/examen-dermatologique-et-gynecologique-avant-azathioprine/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/examen-dermatologique-avant-mycophenolate-mofetil/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/consultation-neurologique-sep-et-cancer/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/evaluation-clinique-et-irm-de-reference/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/avis-oncologique-avant-decision-sep/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/strategie-sep-initiale-en-rct-si-necessaire/ 2026-04-13T13:17:46+00:00 https://sfsep.org/ressource/cyclophosphamide-chez-lhomme/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/corticoides-possibles-en-poussee-malgre-cancer/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/fertilite-et-cyclophosphamide/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/suivi-sep-apres-traitement-initial-du-cancer/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/azathioprine-pendant-la-grossesse/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/avis-oncologique-avant-decision-therapeutique/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/azathioprine-chez-lhomme/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/mycophenolate-mofetil-contre-indique-pendant-grossesse/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/mycophenolate-mofetil-chez-lhomme/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/delai-de-6-semaines-apres-mycophenolate-mofetil/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/ofatumumab-contre-indique-pendant-grossesse/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/ofatumumab-jusquau-diagnostic-de-grossesse/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/arret-de-lofatumumab-a-la-grossesse/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/ofatumumab-en-grossesse-a-discuter/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/rcp-pour-ofatumumab-en-grossesse/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/ofatumumab-chez-lhomme/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/allaitement-possible-sous-ofatumumab/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/reprise-de-lofatumumab-apres-2-semaines/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/delai-de-3-mois-apres-cyclophosphamide/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/recherche-dune-cause-neurologique-liee-au-cancer/ 2026-04-13T13:17:44+00:00 https://sfsep.org/ressource/rcp-pour-anti-cd20-en-grossesse/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/anti-cd20-chez-lhomme/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/alemtuzumab-contre-indique-pendant-grossesse/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/delai-de-4-mois-apres-alemtuzumab/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/surveillance-thyroidienne-apres-alemtuzumab/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/anticorps-thyroidiens-avant-conception/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/alemtuzumab-chez-lhomme/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/cladribine-contre-indiquee-pendant-grossesse/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/delai-de-6-mois-apres-cladribine/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/cladribine-chez-lhomme/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/mitoxantrone-contre-indiquee-pendant-grossesse/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-ponesimod/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/delai-de-4-mois-apres-mitoxantrone/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/anti-cd20-contre-indiques-pendant-grossesse/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/mitoxantrone-chez-lhomme/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/delai-de-2-mois-apres-anti-cd20/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/fertilite-et-mitoxantrone/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/espacement-des-perfusions-danti-cd20/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/cyclophosphamide-contre-indique-pendant-grossesse/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/anti-cd20-en-grossesse-a-discuter/ 2026-04-13T13:17:42+00:00 https://sfsep.org/ressource/natalizumab-au-3e-trimestre/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/reprise-precoce-du-natalizumab-apres-accouchement/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/natalizumab-chez-lhomme/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/fingolimod-contre-indique-pendant-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/delai-de-2-mois-apres-fingolimod/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/relais-du-fingolimod-avant-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/fingolimod-chez-lhomme/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/diroximelfumarate-jusquau-diagnostic-de-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/ponesimod-contre-indique-pendant-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/arret-du-diroximelfumarate-a-la-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/delai-dune-semaine-apres-ponesimod/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/diroximelfumarate-chez-lhomme/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/relais-du-ponesimod-avant-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/allaitement-deconseille-sous-diroximelfumarate/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/ponesimod-chez-lhomme/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/natalizumab-jusquau-diagnostic-de-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/maintien-du-natalizumab-pendant-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/espacement-des-doses-de-natalizumab/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/voie-iv-du-natalizumab-en-grossesse/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/natalizumab-pendant-les-2-premiers-trimestres/ 2026-04-13T13:17:39+00:00 https://sfsep.org/ressource/contraception-sous-teriflunomide/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/teriflunomide-contre-indique-pendant-grossesse/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/teriflunomide-chez-lhomme/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-possible-sous-ocrelizumab-ou-rituximab/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/dimethylfumarate-jusquau-diagnostic-de-grossesse/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-alemtuzumab/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/arret-du-dimethylfumarate-a-la-grossesse/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-cladribine/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/dimethylfumarate-chez-lhomme/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-mitoxantrone/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/diroximelfumarate-contre-indique-pendant-grossesse/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-possible-sous-azathioprine/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-mycophenolate-mofetil/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-cyclophosphamide/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/allaitement-apres-gadolinium/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/interferon-beta-pendant-la-grossesse/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/interferon-beta-chez-lhomme/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/acetate-de-glatiramere-pendant-la-grossesse/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/acetate-de-glatiramere-chez-lhomme/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/arret-et-elimination-du-teriflunomide/ 2026-04-13T13:17:37+00:00 https://sfsep.org/ressource/consultation-neurologique-pendant-grossesse/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-deconseille-sous-dimethylfumarate/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/suivi-obstetrical-standard/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-possible-sous-natalizumab/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/pas-dirm-systematique-pendant-grossesse/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-fingolimod/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/irm-possible-si-necessaire/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/gadolinium-pendant-grossesse/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/prise-en-charge-pluridisciplinaire-de-la-grossesse/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-non-deconseille/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-et-reprise-du-traitement/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/orientation-vers-la-maternite/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/declenchement-programme-de-laccouchement/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/cesarienne-selon-indications-obstetricales/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/reeducation-perineale-du-post-partum/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/analgesie-et-anesthesie-de-laccouchement/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-sous-interferon-beta/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-sous-acetate-de-glatiramere/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/supplementations-vitaminiques-antenatales/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/allaitement-contre-indique-sous-teriflunomide/ 2026-04-13T13:17:35+00:00 https://sfsep.org/ressource/reprise-precoce-des-traitements-apres-accouchement/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/amp-possible-chez-les-femmes-avec-sep/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/amp-apres-12-mois-dinactivite/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/traitement-compatible-maintenu-pendant-lamp/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/techniques-et-protocoles-damp-autorises/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/pas-de-limite-du-nombre-de-tentatives-damp/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/planification-amp-avec-le-neurologue/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/grossesse-non-deconseillee/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/grossesse-apres-12-mois-dinactivite/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/grossesse-possible-apres-6-mois-de-natalizumab/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/grossesse-possible-apres-6-mois-docrelizumab-ou-rituximab/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/pas-dimmunoglobulines-iv-en-grossesse/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/grossesse-possible-apres-6-mois-dofatumumab/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/apherese-en-poussee-severe-pendant-grossesse/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/planification-de-grossesse-avec-le-neurologue/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/methylprednisolone-et-allaitement/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/desir-de-maternite-et-contraception/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/apherese-et-allaitement/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/projet-de-grossesse-et-choix-du-traitement/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-des-poussees-du-post-partum/ 2026-04-13T13:17:32+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-interferon-beta/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-glatiramere/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-teriflunomide/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-fumarate/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-fingolimod/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-cladribine/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-natalizumab/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/depistage-hpv-avant-fingolimod/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/avis-specialise-avant-anti-cd20-et-vhb/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-serologie-jcv-avant-fingolimod/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-prophylaxie-infectieuse-avant-mitoxantrone/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/serologie-vzv-avant-cladribine/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/methylprednisolone-en-poussee-pendant-grossesse/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-serologie-jcv-avant-cladribine/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/methylprednisolone-au-1er-trimestre/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/serologie-jcv-avant-natalizumab/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/serologie-vhb-avant-anti-cd20/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/depistage-hypogammaglobulinemie-avant-anti-cd20/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-serologie-jcv-avant-anti-cd20/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/pas-de-bilan-infectieux-avant-mitoxantrone/ 2026-04-13T13:17:29+00:00 https://sfsep.org/ressource/evaluation-infectieuse-avant-traitement-immunoactif/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/bilan-immunitaire-avant-immunosuppresseur/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/pas-de-bilan-infectieux-avant-interferon-beta/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/vaccination-zona-sous-immunosuppresseur/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/pas-de-bilan-infectieux-avant-glatiramere/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/vaccin-vrs-et-grossesse-sous-immunosuppresseur/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/pas-de-bilan-infectieux-avant-teriflunomide/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/nirsevimab-chez-le-nouveau-ne/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/pas-de-bilan-infectieux-avant-dimethylfumarate/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/traitement-des-infections-urinaires-symptomatiques/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/serologie-vzv-avant-fingolimod/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/antibiocycle-alterne-a-discuter/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/bacteriurie-asymptomatique-pas-de-traitement/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/bacteriurie-avant-immunosuppresseur/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/bacteriurie-avant-bilan-urodynamique-sans-risque/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/bacteriurie-avant-bilan-urodynamique-avec-risque/ 2026-04-13T13:17:27+00:00 https://sfsep.org/ressource/bacteriurie-sous-sondages/ 2026-04-13T13:17:27+00:00